TY - JOUR
T1 - Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia
AU - Serretti, Alessandro
AU - Chiesa, Alberto
AU - Porcelli, Stefano
AU - Han, Changsu
AU - Patkar, Ashwin A.
AU - Lee, Soo Jung
AU - Park, Moon Ho
AU - Pae, Chi Un
N1 - Funding Information:
This work was supported by grants from the Medical Research Center, Korea Science and Engineering Foundation , Republic of Korea (R13-2002-005-04001-0 ) and the Korean Health 21 R & D Project, Ministry of Health and Welfare , Republic of Korea ( A050047 ).
PY - 2011/8/30
Y1 - 2011/8/30
N2 - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.
AB - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.
KW - Bipolar disorder
KW - Major depression
KW - Schizophrenia
KW - Tryptophan hydroxylase 2
UR - http://www.scopus.com/inward/record.url?scp=80051690979&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2011.02.001
DO - 10.1016/j.psychres.2011.02.001
M3 - Article
C2 - 21396719
AN - SCOPUS:80051690979
VL - 189
SP - 26
EP - 32
JO - Psychiatry Research
JF - Psychiatry Research
SN - 0165-1781
IS - 1
ER -
